Talentmark's 40th Anniversary Event
'Futureceuticals' - The industry is looking bright
A Note from Talentmark's Chief Executive Officer, David Nolan
When we started to consider Talentmark's 40th anniversary celebration, the immediate observation was how much has changed and the impact was striking. If you had been able to peer into the future, for the most part it would have been difficult to believe the changes. 40 years ago the current landscape could have been cast as some Orwellian drama that unfolded at an impossible rate and was far too complex to be realistic.
So, marking our 40th year we have attempted to look forward and explore what the future might hold.
I would like to thank Andy, Chris and all those who contributed to the such a rigorous debate. It’s clear that for R&D to work, current models need to change and the challenge to meet the needs of such diverse stakeholders is unlikely to get easier. I was pleased that the presentations and debate covered real issues and offered some interesting approaches to dealing with current challenges. The variety of contributions with very different viewpoints gave real texture to the discussion.
Thanks once again to those who attended our 40th anniversary celebrations. Here’s to many more exciting years ahead.
Kind regards
David Nolan
Chief Executive Officer
Futureceuticals Video I: Andy Black, Kinapse
Andy Black is co-founder of Kinapse, a life sciences specialist consulting and outsourcing firm.
Giving his thoughts on the changes facing the industry, Andy also discusses the challenges of bringing products to market. He shares his vision on future opportunities in the market and some of the recent innovations that are bucking the trend.
Futureceuticals Video II: Chris Brinsmead, Advisor to the UK Government
Chris Brinsmead is Business Advisor to the Department for Business, Innovation & Skills and the Department of Health. He is the recent President of the ABPI and Chair of AstraZeneca Pharma UK.
Appreciating the extensive expertise within assembled group, Chris uses the opportunity to ask the audience questions. This produces a fascinating and informative debate on the future of the pharmaceutical and life sciences industry and issues that need to be addressed.
